HomeAI · summaries
Storia in 3 fonti
Pharmalittle: We're reading about a Biogen Alzheimer's drug, skyrocketing 340B drug sales, and more
An Alzheimer’s drug from Biogen slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved medicines
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.
- ·
statnews.com
Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows
An experimental Alzheimer's drug from Biogen, one with a novel approach, slowed decline at comparable rates as approved drugs in a mid-stage study.
